Souhaitez-vous accéder aux communiqués récents ?

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant...

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in...

SILVER SPRING, MD, April 04, 2025 (GLOBE NEWSWIRE) -- The American Nurses Enterprise, which includes the American Nurses Association, the American Nurses Credentialing Center, and the American...

Wilmington, April 04, 2025 (GLOBE NEWSWIRE) -- In a day when mental clarity and focus are more valuable than ever, many of us are searching for ways to stay sharp—especially as we age. Whether...

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset...

Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus...

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points...

Las Vegas, NV, April 03, 2025 (GLOBE NEWSWIRE) -- EarthCam, the global leader in live camera technology, content and services, is showcasing its industry leading SaaS platform at ISC West. With...

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS® System at the 2025 AAN Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...